Peptide Tools to Study SARS-CoV-2
About SARS-CoV-2
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), the causative agent of coronavirus disease 2019 (Covid-19), is responsible for the 2020 global pandemic. Developing vaccines and therapies that are safe, effective, and rapidly deployable is an urgent global health priority.
JPT's Peptide Tools to Study SARS-CoV2
The global research and development efforts as well as initiation of clinicial trials evaluating vaccines and drugs generated an urgent demand for SARS-CoV-2 related peptide products enabling definition of immune-relevant antigens, identification of B- and T-cell epitopes, development of immune-therapeutic &diagnotic strategies and clinical trial immune monitoring.
In response, JPT has launched a broad development program to provide access to genome spanning SARS-CoV-2 peptide tools to study both humoral and cellular immunity and to support clinicial vaccination trials. Applications for our ready-to-use & customized peptide formats include:
- SARS-CoV-2 Clinical Trial Immune Monitoring
- SARS-CoV-2 Correlation of Cellular and Humoral Immune Responses
- SARS-CoV-2 Evaluation of Cross Reactivities
- SARS-CoV-2 Vaccine Target Identification
- SARS-CoV-2 Blood and Sero Test Development
- SARS-CoV-2 T-and B-cell Epitope Discovery
Cellular Immunity
Please visit the respective product page for detailed information and pricing.
PepMix™ Peptide Pools for
- Antigen-specific T-cell stimulation
- Cellular immune monitoring
- Vaccine target discovery
- Blood test development
- Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
- Cell therapy development
> SARS-CoV-2 PepMixes™ Product Page
> Customized PepMix Pools Product Page
> Clinical grade customized PepMix™ Pools Product Page
> Control Pools Product Page
Epitope Mapping Peptide Sets (EMPS)
- Efficient epitope mapping and identification
- Matrix Pools and individual peptides spanning a whole antigen in one set
- Minimal sample amount required
Antigen Peptides for
- Antigen specific T-cell stimulation in T-cell assays (i.e. ELISpot, ICS)
- Immune monitoring
- Proliferation assays
- T-cell expansion
Humoral Immunity
Please visit the respective product page for detailed information and pricing.
RepliTope™ Pan Coronavirus for
- Humoral immune monitoring
- Antibody epitope discovery
- Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
- Seromarker discovery
> RepliTope™ Pan Coronavirus Product Page
> Customized PepStar™ Peptide Microarrays Product Page
Multiwell RepliTopes™ SARS-CoV-2
- Immune monitoring
- Antibody epitope discovery
- Screening individual antigens of SARS-CoV-2 and SARS
- Seromarker discovery
Three-Step Antibody Response Profiling Service
- High content, peptide resolved antibody response profiling using thousands of tailored peptides covering the entire SARS CoV-2 genome using smallest sample volumes
- Study of antibody cross reactivities between SARS CoV-2 and other corona viruses (HCoVs)
- Verification of the peptide binders using multiwell our array format with large numbers of samples
- Transfer of results to ELISA platform for rapid test development
Peptide ELISA
- Peptide ELISA development and service using your SARS CoV-2 peptides alone or in combination other corona virus (HCoV) peptides
- ELISA based validation service of peptide binders identified using JPT’s peptide microarray platforms
- Collaborative ELISA test development
Clinical Trial Immune Monitoring & Cell Therapy
Please visit the respective product page for detailed information and pricing.
Clinical Grade Peptides & PepMix™ Peptide Pools
- High quality chemically synthesized antigen source for vaccine trial monitoring
- Ancillary reagents for cellular therapy development
- Full analytical coverage, stability testing, batch documentation and more
Proteomics
Please visit the respective product page for detailed information and pricing.
SpikeMix™ SARS-CoV-2 for
- Identify SARS CoV-2 antigens from biological samples
- Mass spectrometry based assays (MRM)
- Screen 23 proteotypic peptides from SARS-CoV-2
References with SARS-CoV-2 Peptide Tools
Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)
More references
Check our list of products,
click and go.
News Highlights
- COVID-19: All Sars-CoV-2 Peptide Products at a Glance
(Aug 2020) - NEW! Study SARS CoV-2 Cross Reactive T-Cells with EMPS-Peptides from Endemic HCoV’s
(July 2020) - NEW! SARS-CoV-2 PepMix™ Peptide Pools & Microarrays
(Mar 2020)
--> Read more News
Quality Assurance
All production is performed according to ISO 9001:2015 standards
